EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world use of the updated refractory epilepsy screening tool for Lennox–Gastaut syndrome

Steven M Wolf iD, Danielle Boyce, Patricia Peña, Jesus Eric Piña-Garza, Jessica J Roland, Bethany Thomas, Donika Zogejani, Patricia E McGoldrick iD

Epilepsia Open · 2024

DOI: 10.1002/epi4.12952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2024. Verfasst von Steven M Wolf und 7 weiteren Autor:innen. Beteiligte Einrichtung: Boston Children's Hospital Physicians, Hawthorne, New York, USA. Hauptthemen laut MEDLINE: Lennox Gastaut Syndrome, Drug Resistant Epilepsy, Electroencephalography. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jazz Pharmaceuticals, Inc., Jazz Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the Refractory Epilepsy Screening Tool for Lennox–Gastaut Syndrome (REST‐LGS) for real‐world identification of LGS in adults and to develop a scoring system for the tool.

Methods

A retrospective chart review of adults with drug resistant epilepsy (DRE) and intellectual development disorder (IDD) was conducted by 2 primary care providers blinded to diagnosis. The REST‐LGS was designed via the Modified Delphi Consensus and was previously validated. This tool consists of 8 criteria (4 major, 4 minor) considered indicative of LGS. To account for missing data in the earlier validation study and to evaluate applicability in a real‐world setting, the REST‐LGS was refined to include a scoring system in which major criteria were more heavily weighted than minor criteria, producing categories of “likely” (>11 points), “possible” (8–11 points), and “unlikely” (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lennox Gastaut SyndromeDrug Resistant EpilepsyElectroencephalographyHumansMaleFemaleAdultRetrospective StudiesYoung AdultIntellectual DisabilityAdolescentMiddle Aged

Stichwörter der Autor:innen

Lennox–Gastaut syndromediagnosisscreening tooltreatment‐resistant epilepsy

Autor:innen und Institutionen

  • Boston Children's Hospital Physicians, Hawthorne, New York, USA.
  • New York Medical College, Valhalla, New York, USA.
  • Tufts University School of Medicine, Boston, Massachusetts, USA.
  • Johns Hopkins School of Medicine, Biomedical Informatics and Data Science, Baltimore, Maryland, USA.
  • The Children's Hospital at TriStar Centennial, Nashville, Tennessee, USA.
  • Jazz Pharmaceuticals, Inc., Carlsbad, California, USA.

ORCID-Profile: Steven M Wolf, Patricia E McGoldrick

Förderung

  • Jazz Pharmaceuticals, Inc.
  • Jazz Pharmaceuticals

Zitieren

APA

Wolf, S. M., Boyce, D., Peña, P., Piña-Garza, J. E., Roland, J. J., Thomas, B., Zogejani, D., & McGoldrick, P. E. (2024). Real‐world use of the updated refractory epilepsy screening tool for Lennox–Gastaut syndrome. Epilepsia Open. https://doi.org/10.1002/epi4.12952

Vancouver

Wolf SM, Boyce D, Peña P, Piña-Garza JE, Roland JJ, Thomas B, et al. Real‐world use of the updated refractory epilepsy screening tool for Lennox–Gastaut syndrome. Epilepsia Open. 2024. doi:10.1002/epi4.12952

BibTeX
@article{Wolf2024,
  author = {Wolf, Steven M and Boyce, Danielle and Peña, Patricia and Piña-Garza, Jesus Eric and Roland, Jessica J and Thomas, Bethany and Zogejani, Donika and McGoldrick, Patricia E},
  title = {Real‐world use of the updated refractory epilepsy screening tool for Lennox–Gastaut syndrome},
  journal = {Epilepsia Open},
  year = {2024},
  doi = {10.1002/epi4.12952}
}
Kostenlos starten →